{'fraction_non_alphanumeric': 0.028049575994781473, 'fraction_numerical': 0.03522504892367906, 'mean_word_length': 5.063241106719367, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of the Long noncoding RNA NONHSAT037832 Gene Expression Changes in Patients with Thyroid Carcinoma

Background & Objective: Thyroid cancer is the most common endocrine disorder in the world. One of the main causes of this cancer is genetic changes, in particular mutations in the tumor and oncogene inhibition genes. In addition to mutations, some non-encoding RNAs called lncRNAs play an important role in the progression of tumors. NONHSAT is a lancer and has recently been referred to the role of this gene in various types of cancer. This study aimed to evaluate the lncRNA-NONHSAT037832 gene expression changes in patients with thyroid carcinoma. 
Materials & Methods: A cross-sectional study was conducted on 140 homogeneous samples (70 cancer tissue homogeneous samples and 70 homogeneous healthy tissue samples) from patients with thyroid cancer referred to Alzahra Hospital in Tabriz. Using the Real-Time PCR, changes in the expression of the lncRNA-NONHSAT037832 gene were evaluated. In addition, the relationship between lncRNA-NONHSAT037832 gene expression changes and clinical parameters was investigated. 
Results: The results showed that the expression of lncRNA-NONHSAT037832 gene expression in the tissues of cancer was significantly higher than healthy tissues (P <0.001) and a significant relationship with MTN (P = 0.001) and node metastasis Lymphoma was shown (P = 0.30). 
Conclusion: According to the results, the lncRNA-NONHSAT037832 gene may be used as a prognostic biomarker for thyroid cancer. 
 